-+ 0.00%
-+ 0.00%
-+ 0.00%

Leerink Partners Downgrades Akebia Therapeutics to Market Perform, Announces $1 Price Target

Benzinga·08/08/2026 00:20:42
Listen to the news
Leerink Partners analyst Roanna Ruiz downgrades Akebia Therapeutics (NASDAQ:AKBA) from Outperform to Market Perform and announces $1 price target.